- Home
- NAMI vs TCRX Comparison
NAMI vs TCRX Comparison
Compare NAMI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMI
- TCRX
- Stock Information
- Founded
- NAMI 2014
- TCRX 2018
- Country
- NAMI China
- TCRX United States
- Employees
- NAMI N/A
- TCRX N/A
- Industry
- NAMI
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- NAMI
- TCRX Health Care
- Exchange
- NAMI NYSE
- TCRX Nasdaq
- Market Cap
- NAMI 286.0M
- TCRX 257.5M
- IPO Year
- NAMI 2024
- TCRX 2021
- Fundamental
- Price
- NAMI $5.19
- TCRX $3.08
- Analyst Decision
- NAMI
- TCRX Strong Buy
- Analyst Count
- NAMI 0
- TCRX 5
- Target Price
- NAMI N/A
- TCRX $11.40
- AVG Volume (30 Days)
- NAMI 519.9K
- TCRX 435.3K
- Earning Date
- NAMI 02-11-2025
- TCRX 11-12-2024
- Dividend Yield
- NAMI N/A
- TCRX N/A
- EPS Growth
- NAMI N/A
- TCRX N/A
- EPS
- NAMI 0.37
- TCRX N/A
- Revenue
- NAMI $56,127,097.00
- TCRX $9,362,000.00
- Revenue This Year
- NAMI N/A
- TCRX N/A
- Revenue Next Year
- NAMI N/A
- TCRX $4.11
- P/E Ratio
- NAMI $11.30
- TCRX N/A
- Revenue Growth
- NAMI 64.40
- TCRX N/A
- 52 Week Low
- NAMI $3.75
- TCRX $2.60
- 52 Week High
- NAMI $7.75
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- NAMI N/A
- TCRX 32.41
- Support Level
- NAMI N/A
- TCRX $2.82
- Resistance Level
- NAMI N/A
- TCRX $3.15
- Average True Range (ATR)
- NAMI 0.00
- TCRX 0.39
- MACD
- NAMI 0.00
- TCRX -0.12
- Stochastic Oscillator
- NAMI 0.00
- TCRX 20.09
About NAMI JINXIN TECHNOLOGY HOLDING COMPANY SPONSORED ADS EACH REP 18 ORD SHS
Jinxin Technology Holding Co is a company which operates through its subsidiaries are principally engaged in provision of digital textbook subscription services in the People's Republic of China. The Company generates revenue by selling its content to hardware manufacturers in China whereby they are allowed to install the Company's digital educational content on the manufacturers' devices for sale to end users.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.